Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

1 week ago 38
Dokky PRO Bookcase Shop
Viking Therapeutics VKTX announced positive 52-week histologic data from the phase IIb VOYAGE study that evaluated VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

BankB.it shares this Content with License.

Read Entire Article

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results